Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Phase III data show significant reductions in blood glucose with investigational compound empagliflozin used as monotherapy in adults with type 2 diabetes
Phase III data show significant reductions in blood glucose with investigational compound empagliflozin used as monotherapy in adults with type 2 diabetes
Phase III data show significant reductions in blood glucose with investigational compound empagliflozin used as monotherapy in adults with type 2 diabetes
Submitted by
admin
on June 23, 2013 - 11:20am
Source:
Yahoo/PR NewsWire
News Tags:
empagliflozin
type 2 diabetes
diabetes
Boehringer Ingelheim
Headline:
Phase III data show significant reductions in blood glucose with investigational compound empagliflozin used as monotherapy in adults with type 2 diabetes
Do Not Allow Advertisers to Use My Personal information
